MET and breast carcinoma: The breast cancer cohort consisted of 1320 samples, 644 (49%) of which harbored pathogenic ctDNA mutations, with the most commonly mutated genes being TP53 (23%), PIK3CA (19%), ESR1 (18%), and AKT1/MET (4%).